For a complete list, see my Google Scholar profile .
Agrawal, R., Weiner, A.B., Livingstone, J., Pooli, A., Huang, R.R., Ye, H., Sisk, A., Elashoff, D.A., Boutros, P.C., Rettig, M.B., and Reiter, R.E. (2025). Neoadjuvant Antiandrogen Therapy With or Without MEK or SRC Inhibition for Unfavorable-risk Prostate Cancer: A Phase 2 Randomized Clinical Trial. Eur Urol Oncol. doi:10.1016/j.euo.2025.10.013 .
Agrawal, R., Al-Hiyari, S., Hugh-White, R., Hromas, R., Patel, Y., Williamson, E.A., et al. (2025). Colibactin Exerts Androgen-Dependent and -Independent Effects on Prostate Cancer. Eur Urol Oncol. doi:10.1016/j.euo.2024.10.015 .
Weiner, A.B., Agrawal, R., Wang, N.K., Sonni, I., Li, E.V., Arbet, J., et al. (2024). Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer. Eur Urol. doi:10.1016/j.eururo.2024.09.005 .
Weiner, A.B., Agrawal, R., Valle, L.F., Sonni, I., Kishan, A.U., Rettig, M.B., Raman, S.S., Calais, J., Boutros, P.C., and Reiter, R.E. (2024). Impact of PSMA PET on Prostate Cancer Management. Curr Treat Options Oncol. doi:10.1007/s11864-024-01181-9 .
Crowell, P.D., Giafaglione, J.M., Jones, A.E., Nunley, N.M., Hashimoto, T., Delcourt, A.M.L., Petcherski, A., Agrawal, R., et al. (2023). MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer. Cell Reports 42. doi:10.1016/j.celrep.2023.113221 .
Agrawal, R., and Prabakaran, S. (2020). Big data in digital healthcare: lessons learnt and recommendations for general practice. Heredity 124, 525-534. doi:10.1038/s41437-020-0303-2 .
Agrawal, R. “Genomic Markers of Aggression in Prostate Cancer Model Systems.” Jonsson Comprehensive Cancer Center (JCCC) Symposium, Los Angeles, CA. May 2025.
Agrawal, R. “Dissecting Prostate Cancer Heterogeneity.” Prostate Cancer SPORE Meeting, Los Angeles, CA. February 2025.
Agrawal, R. “The Role of the Microbiome in Prostate Cancer.” Department of Human Genetics Works in Progress Series, UCLA, Los Angeles, CA. November 2024.